These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28934561)

  • 1. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.
    Angus SP; Zawistowski JS; Johnson GL
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():209-229. PubMed ID: 28934561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.
    Mancini M; Yarden Y
    Semin Cell Dev Biol; 2016 Feb; 50():164-76. PubMed ID: 26428295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition.
    East MP; Johnson GL
    J Biol Chem; 2022 Feb; 298(2):101525. PubMed ID: 34958800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
    Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
    Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.
    Faes S; Demartines N; Dormond O
    Oxid Med Cell Longev; 2017; 2017():1726078. PubMed ID: 28280521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance.
    Guo L; Lee YT; Zhou Y; Huang Y
    Semin Cancer Biol; 2022 Aug; 83():487-502. PubMed ID: 33421619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue.
    Stratikopoulos EE; Parsons RE
    Clin Cancer Res; 2016 Jun; 22(11):2605-10. PubMed ID: 27250929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
    Cacabelos R
    Drug Dev Res; 2014 Sep; 75(6):348-65. PubMed ID: 25195579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Kinase inhibitors and their resistance].
    Togashi Y; Nishio K
    Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptors as treatment targets in clinical oncology.
    Katoh M
    Nat Rev Clin Oncol; 2019 Feb; 16(2):105-122. PubMed ID: 30367139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
    Whittaker S; Kirk R; Hayward R; Zambon A; Viros A; Cantarino N; Affolter A; Nourry A; Niculescu-Duvaz D; Springer C; Marais R
    Sci Transl Med; 2010 Jun; 2(35):35ra41. PubMed ID: 20538618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance, epigenetics, and tumor cell heterogeneity.
    Hoey T
    Sci Transl Med; 2010 Apr; 2(28):28ps19. PubMed ID: 20410528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance.
    Ponnusamy L; Mahalingaiah PKS; Singh KP
    Adv Clin Chem; 2020; 94():219-259. PubMed ID: 31952572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emergence of drug resistance to targeted cancer therapies: Clinical evidence.
    Sarmento-Ribeiro AB; Scorilas A; Gonçalves AC; Efferth T; Trougakos IP
    Drug Resist Updat; 2019 Dec; 47():100646. PubMed ID: 31733611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.